---
title: "FOSUN PHARMA Luvometinib Tablets Granted Approval for New Indication"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289855255.md"
description: "Fosun Pharma announced that the National Medical Products Administration (NMPA) has approved Luvometinib Tablets for a new indication: treating pediatric patients aged 2 and older with relapsed or refractory Langerhans cell histiocytosis (LCH) after systemic therapy. As of May 2026, the company had invested approximately RMB699 million in the drug's research and development."
datetime: "2026-06-16T02:50:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289855255.md)
  - [en](https://longbridge.com/en/news/289855255.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289855255.md)
generator: "portal-rs"
---

# FOSUN PHARMA Luvometinib Tablets Granted Approval for New Indication

FOSUN PHARMA (02196.HK) -0.100 (-0.612%) Short selling $1.82M; Ratio 5.556% announced that recently, the drug registration application for the additional indication of Luvometinib Tablets, has been approved by the National Medical Products Administration (NMPA). The approved indication is for the treatment of pediatric patients 2 years of age and older with relapsed or refractory Langerhans cell histiocytosis (LCH) after systemic therapy.

As of May 2026, the Group had invested approximately RMB699 million in total in the research and development of the Drug at this stage.  
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-15 16:25.)

### Related Stocks

- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)
- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)

## Related News & Research

- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [Shanghai Fosun Pharma files HKEX next-day return after share buyback at HKD 16.21 each](https://longbridge.com/en/news/297627984.md)
- [Peptide innovator says the drug class is due for a rethink](https://longbridge.com/en/news/297803292.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [SSY Group says China NMPA clears generic consistency review for diltiazem tablets 30 mg](https://longbridge.com/en/news/297758026.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**